COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE PCV20 VERSUS PCV13 FOLLOWED BY PPV23 IN THE ALGERIAN ADULT POPULATION
Author(s)
Dimitra Anglou, MSc.1, Liping Huang, MD2, Sara Derki, PharmD3, Hanae Zarrik, PhD4, Jalila Enzrati Jalal, MSc4, Baya Boulila, MD4.
1Pfizer Inc., Tadworth, Surrey, United Kingdom, 2Pfizer Inc., Washington Crossing, PA, USA, 3Pfizer, Alger, Algeria, 4Pfizer, Casablanca, Morocco.
1Pfizer Inc., Tadworth, Surrey, United Kingdom, 2Pfizer Inc., Washington Crossing, PA, USA, 3Pfizer, Alger, Algeria, 4Pfizer, Casablanca, Morocco.
OBJECTIVES: Pneumococcal disease remains a significant burden in Algerian adults. Current strategies include sequential vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23). Following the introduction of the 20-valent pneumococcal conjugate vaccine (PCV20), the study evaluated the health and economic impact of a single dose of PCV20 compared with PCV13→PPV23 in the Algerian adult population (18-99-year-olds).
METHODS: A decision-analytic Markov model assessed PCV20 versus PCV13→PPV23 in Algerian adults stratified into age groups of 18-49, 50-64, 65-74, 75-84, 85-99 years, from a public healthcare payer perspective for a lifetime horizon. Epidemiological inputs, including incidence, case fatality rates, and serotype distribution, were obtained from the Global Burden of Disease study and published sources. Algerian-specific cost inputs were obtained from a local hospital survey in 2023 and adjusted to 2026 inflation. Vaccine effectiveness assumptions were aligned with previous similar studies. Clinical outcomes, including invasive pneumococcal disease (IPD) cases, non-bacteraemic pneumococcal pneumonia (NBP) cases, deaths, associated direct medical costs, and quality-adjusted life-years (QALY), were estimated over a lifetime horizon with 3% annual discounting.
RESULTS: PCV20 was projected to prevent an additional 817 IPD cases (including bacteraemia and meningitis), 33,332 NBP cases, and 1,317 deaths compared with PCV13→PPV23, of which 55.5% of deaths averted would occur in the high-risk population. These additional health gains translated into substantial cost savings, with PCV20 associated with savings of approximately DZD 15.2 million. Considering the QALY gain, PCV20 was estimated to be the cost-saving (dominant) vaccination strategy.
CONCLUSIONS: From the Algerian healthcare payer perspective, a single dose of PCV20 is the dominant strategy compared with PCV13→PPV23,and is associated with improved health outcomes and cost savings . Adoption of PCV20 may contribute to reducing pneumococcal disease burden and improving the efficiency of healthcare resource use in adults.
METHODS: A decision-analytic Markov model assessed PCV20 versus PCV13→PPV23 in Algerian adults stratified into age groups of 18-49, 50-64, 65-74, 75-84, 85-99 years, from a public healthcare payer perspective for a lifetime horizon. Epidemiological inputs, including incidence, case fatality rates, and serotype distribution, were obtained from the Global Burden of Disease study and published sources. Algerian-specific cost inputs were obtained from a local hospital survey in 2023 and adjusted to 2026 inflation. Vaccine effectiveness assumptions were aligned with previous similar studies. Clinical outcomes, including invasive pneumococcal disease (IPD) cases, non-bacteraemic pneumococcal pneumonia (NBP) cases, deaths, associated direct medical costs, and quality-adjusted life-years (QALY), were estimated over a lifetime horizon with 3% annual discounting.
RESULTS: PCV20 was projected to prevent an additional 817 IPD cases (including bacteraemia and meningitis), 33,332 NBP cases, and 1,317 deaths compared with PCV13→PPV23, of which 55.5% of deaths averted would occur in the high-risk population. These additional health gains translated into substantial cost savings, with PCV20 associated with savings of approximately DZD 15.2 million. Considering the QALY gain, PCV20 was estimated to be the cost-saving (dominant) vaccination strategy.
CONCLUSIONS: From the Algerian healthcare payer perspective, a single dose of PCV20 is the dominant strategy compared with PCV13→PPV23,and is associated with improved health outcomes and cost savings . Adoption of PCV20 may contribute to reducing pneumococcal disease burden and improving the efficiency of healthcare resource use in adults.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE594
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Disease
Geriatrics, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines